Claims for Patent: 8,410,045

Summary for Patent: 8,410,045

Title:	Camptothecin-peptide conjugates and pharmaceutical compositions containing the same
Abstract:	The present invention relates to a novel compound of use in the improved delivery of therapeutic drug agents into target cells or tissues, composition comprising the same and uses thereof. The compound is more specifically a conjugate of a peptide moiety and a camptothecin, a derivative or analog thereof which provides numerous benefits, including enhancement in terms of aqueous solubility, pharmacokinetics and tissue distribution, enlargement of the therapeutic index, and limitation of the inter-patient metabolic variability, as well as improvement of delivery of the biologically active ingredient to the target cells or tissues.
Inventor(s):	Michel; Matthieu (Le Vesinet, FR), Ravel; Denis (Paris, FR), Ribes; Fabien (Marseille, FR), Tranchant; Isabelle (Le Kremlin-Bic tre, FR)
Assignee:	Drais Pharmaceuticals, Inc. (Bridgewater, NJ)
Application Number:	12/295,508
Patent Claims:	1. A conjugate comprising at least one camptothecin, wherein said conjugate has the following formula (VI): ##STR00036## wherein X represents a cell penetrating peptide (CPP), which is attached to the remainder of the conjugate by a thioether bond, wherein the cell penetrating peptide comprises an amino acid sequence selected from the group consisting of: DPV3 (SEQ ID NO: 1): Arg Lys Lys Arg Arg Arg Glu Ser Arg Lys Lys Arg Arg Arg Glu Ser DPV6 (SEQ ID NO: 2): Gly Arg Pro Arg Glu Ser Gly Lys Lys Arg Lys Arg Lys Arg Leu Lys Pro DPV7 (SEQ ID NO: 3): Gly Lys Arg Lys Lys Lys Gly Lys Leu Gly Lys Lys Arg Asp Pro DPV7b (SEQ ID NO: 4): Gly Lys Arg Lys Lys Lys Gly Lys Leu GIy Lys Lys Arg Pro Arg Ser Arg DPV10 (SEQ ID NO: 5): Ser Arg Arg Ala Arg Arg Ser Pro Arg His Leu Gly Ser Gly DPV3/10 (SEQ ID NO: 6): Arg Lys Lys Arg Arg Arg Glu Ser Arg Arg Ala Arg Arg Ser Pro Arg His Leu DPV10/6 (SEQ ID NO: 7): Ser Arg Arg Ala Arg Arg Ser Pro Arg Glu Ser Gly Lys Lys Arg Lys Arg Lys Arg DPV1047 (SEQ ID NO: 8): Val Lys Arg Gly Leu Lys Leu Arg His Val Arg Pro Arg Val Thr Arg Met Asp Val DPV1048 (SEQ ID NO: 9): Val Lys Arg Gly Leu Lys Leu Arg His Val Arg Pro Arg Val Thr Arg Asp Val DPV15 (SEQ ID NO: 10): Leu Arg Arg Glu Arg Gln Ser Arg Leu Arg Arg Glu Arg Gln Ser Arg and DPV15b (SEQ ID NO: 11): Gly Ala Tyr Asp Leu Arg Arg Arg Glu Arg Gln Ser Arg Leu Arg Arg Arg Glu Arg Gln Ser Arg; Y represents the camptothecin and is represented by: ##STR00037## wherein t is 0, 1 or 2 and Z is a --COO--group or a substituted or unsubstituted divalent alkyl group; Y is attached to the remainder of the conjugate by an ester bond, a carbonyl-disulfide bond or a carboxy-thioester bond; B is a cyclo(C.sub.3--C.sub.8)alkyl, R.sub.1 is a (C.sub.1--C.sub.8) alkyl, optionally interrupted by at least one cycloalkyl group, and optionally interrupted by at least one divalent radical selected from --CONR'--and --NR''OC(O) --, wherein R' and R'' independently from each other are selected from hydrogen and (C.sub.1--C.sub.8) alkyl; and R.sub.2 is a (C.sub.1--C.sub.8) alkyl interrupted by at least one cycloalkyl group, said (C.sub.1--C.sub.8) alkyl optionally interrupted by at least one divalent radical selected from --OC(O)--, --CO.sub.2--, --CONR'--, --NR'CO--, --OC(O)NR'--, and --NR''C(O).sub.2--, wherein R' and R'' independently from each other are selected from hydrogen and (C.sub.1--C.sub.8) alkyl. 2. The conjugate according to claim 1, wherein Y is represented by the following formula (III): ##STR00038## 3. The conjugate according to claim 2, wherein Y is represented by the following formula (IV): ##STR00039## 4. The conjugate according to claim 1, wherein the camptothecin is selected from the group consisting of irinotecan, topotecan, GI-1472 11C, SN38, 7-hydroxymethyl camptothecin, 9-aminocamptothecin, 7-aminomethyl camptothecin, 10-hydroxycamptothecin and (20S)-camptothecin. 5. The conjugate according to claim 1, wherein --R.sub.1 is --CH.sub.2--or --CH.sub.2CH.sub.2--. 6. The conjugate according to claim 1, wherein camptothecin is linked covalently to the cell penetrating peptide with a linker resulting from a compound selected from: 4-[(N-maleimidomethyl)cyclohexane-1-carboxy-6-amidohexanecarboxamido methyl]cyclohexanecarboxylic acid and 4-[((N-maleimidomethyl)cyclohexanecarboxamido)methyl]cyclohexanecarboxyli- c acid. 7. The conjugate according to claim 1, wherein the peptide is derived from a human heparin binding protein and capable of penetrating into a cell or tissue and comprises: - DPV1047 (SEQ ID NO: 8): Val Lys Arg Gly Leu Lys Leu Arg His Val Arg Pro Arg Val Thr Arg Met Asp Val. 8. The conjugate according to claim 7, wherein the peptide presents a cysteine at the C or N position. 9. The conjugate according to claim 1, which is selected from the group consisting of: ##STR00040## ##STR00041## 10. A pharmaceutical composition comprising a pharmaceutically acceptable carrier and at least one conjugate of claim 1. 11. A method for treating cancer comprising administering an effective amount of the pharmaceutical composition according to claim 10 to a subject in need thereof, wherein said cancer is colon cancer, small cell lung cancer, non-small cell lung cancer, bronchic cancer, pancreatic cancer, ovarian cancer, breast cancer, prostate cancer, liver cancer, head cancer, stomach cancer, neck cancer, bladder cancer, non-Hodgkin's lymphoma, melanoma, leukaemia, neuroblastoma, or glioblastoma. 12. The method of claim 11, wherein the composition is administered orally, intra-cranially, intra-spinally, enterally or parenterally. 13. The method of claim 11, wherein the composition is administered simultaneously or sequentially with other therapeutic regimens or agents. 14. The method of claim 11, comprising a simultaneous or sequential administration with other therapeutic regimens or agents, selected from the group consisting of 5-fluorouracil, leucovorin, oxaliplatine, capecitabine, vincristine, celebrex, temozolomide, selenium, thalidomide, cetuximab, gemcitabine, docetaxel, 3-AP, carboplatine, bortezomib, bevacizumab, sorafenib, cisplatin, gefitinib, flavopiridol, elvorine, carboplatin, amrubicin, trastuzumab, pemetrexed, erlotinib, mitomycin C, AMG706, panitumumab, paclitaxel, raltitrexed, imatinib, abciximab, infliximab, palivizumab, rituximab, gemtuzumab ozogamicin, alemtuzumab, and ibritumomab tiuxetan.

Details for Patent 8,410,045

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Janssen Biotech, Inc.	REOPRO	abciximab	Injection	103575	12/22/1994		2026-03-30
Genentech, Inc.	RITUXAN	rituximab	Injection	103705	11/26/1997		2026-03-30
Idec Pharmaceuticals Corp.	RITUXAN	rituximab	Injection	103737	02/19/2002		2026-03-30
Swedish Orphan Biovitrum Ab (publ)	SYNAGIS	palivizumab	For Injection	103770	06/19/1998		2026-03-30
Swedish Orphan Biovitrum Ab (publ)	SYNAGIS	palivizumab	Injection	103770	07/23/2004		2026-03-30